Financial impact and patient satisfaction with four different anticoagulants for hip and knee arthroplasty in patients with a previous history of VTE- A prospective randomised trial New generation oral anticoagulants (dabigatran/rivaroxaban) have recently become available for the prevention of venous thromboembolism (VTE) following hip and knee arthroplasty. Traditional therapies (warfarin/low molecular weight heparins) are less costly, but have several limitations. The aim of this study was to evaluate the financial impact of substituting enoxaparin and warfarin with newer therapies dabigatran and rivaroxaban. A secondary objective was to investigate patient satisfaction with these treatments. A randomised prospective study was conducted over a 12 month period. Patients with a history of VTE undergoing hip or knee replacement were randomised to receive one of four anticoagulants for five weeks post surgery. Information was gathered during the hospital stay and then post discharge, by telephone, for five weeks(35 days)to determine costs. The costs included cost of drug, nursing time, blood monitoring and transport costs. The patients were also asked to complete the Duke Anticoagulation Satisfaction Scale (DASS). The DASS is a 26 item questionnaire which has 7 responses for each question.Introduction
Methods
Patients presenting with a fractured neck of femur are a fragile group with multiple co-morbidities who are at risk of post-operative complications. As many as 52% of patients are reported to suffer a urinary tract infection post hip fracture surgery. There are little data surrounding the effects of post-operative urinary tract infections on mortality and deep prosthetic infection. We prospectively investigated the impact of post-operative urinary tract infection (UTI) in 9168 patients admitted to our institution with a diagnosis of proximal femoral fracture over an eleven year period in a prospective population study. We examined the effects of post operative UTI on the incidence of deep infection, survivorship and length of stay. Post-operative UTI occurred in 6.1% (n=561) and deep infection in 0.89% (n=82). Deep infection was significantly more common in patients complicated with a UTI (3.2% vs 0.74% p< 0.001) with a relative risk of 3.7:1. In 58% of patients the same organisms was cultured in the urine and hip samples. A postoperative UTI did not adversely effect 90 day survival, however was associated with an increased length of stay (ROC analysis AUC=0.79). Delays to surgery and age were not predictive of a post operative UTI. Recognition of the risks posed by post operative UTI, the risk factors for development of infection and early treatment is essential to reduce the risks of increased subsequent periprosthetic infection.
We present the results of 15 patients revised with a Compress® prosthesis secondary to failure of other distal femur reconstruction. One prosthesis had to be removed because of deep infection. Three patients needed a second surgery due to a vertical crack proximal to the anchor plug at the level of a cortical bone defect. At last follow-up, radiologic evaluation of the entire series showed a mean bone growth ratio higher than did preoperative radiographs. All patients had mainly good or excellent MSTS functional results. Distal femoral prosthetic replacement with a Compress® implant in severe cases of bone loosening and instability provides a reliable reconstruction alternative that promotes bone formation. Patients with cortical defects proximal to the anchor plug should be protected with extracortical supports.
The objective of this study was to compare the results of two consecutive series of patients with either intra-medullary uncemented stems (UCS) distal femoral endoprosthetic replacement or the Compress® (CMP) distal femoral implant. Patients were divided into two groups: those who received UCS prosthesis (Group-1: 54 patients) and those who received CMP prosthesis (Group-2: 42 patients).The most frequent diagnosis was osteosarcoma. Age and gender were similar both groups. In Group-1, at a mean follow-up of 144 months, 37 prostheses were still in place. The overall Kaplan-Meier prosthetic survival rates were 79% at five and 62 % at ten years. Most of failures were long term complications. Aseptic loosening was the primary cause of late prosthetic failure. On Cox regression analysis, prosthetic stem diameter under 13mm was a significant negative prognostic factor for prosthetic survival (p=0.016). In Group-2, at a mean follow-up of 84 months, 36 prostheses were still in place. The overall rate of CMP prosthesis survival was 86% at 5 years. All complications were during the first postoperative year, being femoral fracture the main revision cause. The patients who retained the prosthesis had mainly good or excellent MSTS functional results in both groups.
